Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HOW TO PLAY IT: Wading back into European equities

Fri, 18th Jan 2013 18:42

By David Randall

NEW YORK, Jan 18(Reuters) - After more than three years ofcrisis, Europe's days as a no-man's land may be coming to anend.

The Euro Stoxx 50, an index of blue chip European stocks, isup more than 30 percent as of Thursday from the low it hit onJune 1. It gained a total of 11.2 percent in 2012.

Driving this rally is the pledge by the European CentralBank to support the euro by any means necessary. It lowered therisk that Greece would leave the euro zone and potentially breakup the currency union, and drove bond yields in Spain down fromcrisis levels.

With fears of a worst-case scenario subsiding, institutionalinvestors have been increasing their allocations to Europeanstocks, according to a Bank of America Merrill Lynch surveypublished Tuesday.

Analysts and portfolio managers say that the push is moreakin to wading back into the pool than taking a full dive. Withan unemployment rate of 11.8 percent and an economy that shrunkby 0.1 percent in its most recent quarter, this may be a time tocautiously add exposure to the euro zone, rather than try tochase the market.

Here are ways these U.S. fund managers and financialadvisers are increasing stakes in Europe.

BUYING SELECTIVELY

Even after the market's 2012 rebound, financial andindustrial stocks look attractive on a valuation basis, saidChad Deakins, portfolio manager of the $280 million RidgeWorthInternational Equity fund. Deakins has about 65percent of his assets in European stocks now, compared with lessthan 60 percent at the beginning of last year.

Deakins is focusing most of his portfolio on Germany andFrance, but maintains that it's still too early to increaseexposure to companies in Spain, Portugal or Ireland, which havehigher unemployment rates and financially strapped governments.

Among his picks: French bank BNP Paribas SA andAustrian bank Raiffeisen Bank International AG, bothof which trade at price to book ratios of 0.73 or below and forless than 9 times earnings. Deakins says each bank should tradeat 1.5 times book value.

Raiffeisen has particularly attractive growth prospectsbecause it makes loans in emerging European markets like Poland,he said. The company is already up 6.1 percent for the year, andcomes with a dividend yield of 3.1 percent.

Deakins has also been buying shares of industrial companiesthat have exposure to emerging markets like China and India,such as German chemical company BASF, Frenchtire-maker Michelin, and French energy company TotalSA.

Other fund managers are eschewing European industrialcompanies for pharmaceutical, telecom and utilities stocks thathaven't rallied as sharply as financials and consumer stocks.

"The volatility in Europe over the 12-month period createdvery good entry prices," said Suzanne Hutchins, a portfoliomanager of the $81 million Dreyfus Global Real Return fund.

Hutchins, who recently increased her stake in Europe to 19percent of assets from 13 percent of assets in April as part ofa global increase in riskier securities, is focusing oncompanies with large dividends and strong cash flows. Among herlarger positions: British pharmaceutical GlaxoSmithKline PLC, Swiss biotech Roche Holding AG, and Frenchpharma company Sanofi. Roche, for instance, offers adividend yield of 3.4 percent and is up 23.7 percent over thelast year through Thursday.

FUND OPTIONS

Some financial advisers are opting for funds over individualsecurities. Tony Zabigeala, vice president at Strategic WealthPartners in Seven Hills, Ohio, recently increased his stake inEurope to 25 percent of assets from 10 percent of assets.

Zabigeala invests in Europe mainly through the SPDR EuroStoxx 50 ETF (FEZ), a $1.4 billion fund that costs 29 cents per$100 invested and yields 3.7 percent.

"We expect to see a leadership change from U.S. equities toeurozone stocks this year," Zabigeala said.

Investors in the fund should note that it excludes holdingsin the U.K. and Switzerland, which "magnifies its exposure tothe weakest members of the euro zone, including Italy andSpain", noted Alex Bryan, a fund analyst at Morningstar.

Another euro bull is Will McGough, vice president ofportfolio management at Stadion Money Management. McGough loadedup on European stocks, boosting his fund's exposure to 21percent of assets from 4.9 percent of assets in the $13.5million Stadion Olympus Fund between April andDecember. The fund, which aims to follow market momentum, holdsa basket of ETFs instead of individual shares.

McCough has been buying shares of the $4.1 billion iSharesMSCI Germany ETF (EWG), targeting exporters that benefit fromemerging market growth and the U.S. economy. It costs 53 centsper $100 invested and yields 2.3 percent. The fund is up 24.6percent over the last year, according to Morningstar.

"Basically last year Europe went into a bear market in thefirst half of the year, and we're still seeing the recovery fromthat," McCough said.

More News
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.